Terry Fox Laboratory | Dr. Donna Hogge

Home » Research Labs » Donna E. Hogge

About
Research Interest
Publications
Lab People
Open Positions

About

Dr. Donna Hogge, MD, PhD, FRCPC
Senior Scientist

Member, Leukemia Bone Marrow Transplant Program of BC
Clinical Professor, Medicine, University of British Columbia (UBC)
Member, Genetics, University of British Columbia (UBC)
Member, Experimental Medicine, University of British Columbia (UBC)
Associate Member, Pathology & Laboratory Medicine, University of British Columbia (UBC)

Research Interest

Molecular regulation of normal and malignant human hemopoiesis
Growth Factors, Leukemia, Gene Transfer, Target Drug Therapy

The maintenance of adequate numbers of functional blood cells is a complex process involving regulation of cell growth, maturation and ultimately cell death. The precise way in which the orderly production of these cells is controlled in vivo in man is unknown, although many regulators have now been identified.

Normal growth responses are often perturbed in leukemic blood cells and disordered regulation of cell proliferation and maturation are hallmarks of all human hematologic malignancies. The goal of my research is to understand normal regulatory mechanisms and the abnormalities that result in malignant transformation of hematopoietic cells. Such knowledge should allow the development of novel therapeutic agents that specifically target leukemic cells.

Culture conditions have been developed which support the growth of normal and leukemic hematopoietic cells for many weeks. In addition, immunodeficient mice provide convenient hosts for the growth of these cells. These systems are being used to compare the regulation of cell cycle control and growth factor-mediated signal transduction in normal and malignant hematopoietic progenitor cells. Drug treatments and gene transfer strategies are used to manipulate these cells in vitro and in vivo and the effects on cell targets compared. Novel therapeutic agents engineered to target leukemic cells are undergoing preclinical testing to assess their suitability for clinical trials in leukemia patients.

Ultimately it is hoped that these studies will lead not only to improved understanding of basic growth control of hemopoietic cells but also to improved results in the treatment of leukemia and the use of bone marrow transplantation in man.

Publications

Selected Publications

2011

Cameron C, Tantiworawit A, Halpenny M, Letcher B, Berrigan S, Hindmarsh K, Giftakis A, Fortier J, O'Hoski P & Hogge D. Cryopreserved mobilized autologous blood progenitors stored for more than two years successfully support blood count recovery after high dose chemotherapy. Cytotherapy 13: 856-863, 2011. View Abstract

Kim HP, Gerhard B, Harasym TO, Mayer LD & Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 39: 741-750, 2011. View Abstract

2010

Kim HP, Frankel AE & Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res 34: 1035-1042, 2010. View Abstract

Muranyi A, Dedhar S & Hogge DE. Targeting integrin linked kinase and Fms-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res 34: 1358-1365, 2010. View Abstract

2009

Muranyi AL, Dedhar S & Hogge DE. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 37: 450-460, 2009. View Abstract

2008

Ho MM, Hogge DE & Ling V. MDR1 and BCRP1 expression in leukemic progenitors predicts chemotherapy response in acute myeloid leukemia. Exp Hematol 36: 433-442, 2008. View Abstract

2006

Yalcintepe L, Frankel AE, & Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108 (10): 3530-7, 2006. View Abstract

Hogge DE, Yalcintepe L, Wong SH, Gerhard B, & Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12 (4): 1284-91, 2006. View Abstract

2004

Hogge DE, Feuring-Buske M, Gerhard B, & Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res 28 (11): 1221-6, 2004. View Abstract

2003

Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, & Hogge DE. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17 (4): 760-3, 2003. View Abstract

Guan Y, Gerhard B, & Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101 (8): 3142-9, 2003. View Abstract

2002

Guan Y, Ralph S, & Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 30 (7): 721-8, 2002. View Abstract

Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, & Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62 (6): 1730-6, 2002. View Abstract

2000

Guan Y, & Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14 (12): 2135-41, 2000. View Abstract

Lab People

Postdoctoral Fellow

Dr. Yan Xing

Graduate Students

Research Assistant

Gitte Gerhard

Research Student
Sofie Perdu

Open Positions

None Available at this time.

Mailing Address:

Terry Fox Laboratory
BC Cancer Agency
675 West 10th Avenue
Vancouver BC
Canada V5Z 1L3

Email:

dhogge@bccancer.bc.ca

Phone Number: